Antifungal drug resistance in pathogenic fungi

Medical Mycology, Supplement

Volumn 36, Issue 1, 1998, Pages 119-128

  Vanden Bossche, H ^a   Dromer, F ^b   Improvisi, I ^b   Lozano Chiu, M ^c   Rex, J H ^c   Sanglard, D ^d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Amphotericin; Aspergillus; Azoles; Candida; Cryptococcus; Flucytosine; Resistance; Terbinafine

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MEMBRANE LIPID; POSACONAZOLE; PYRIMIDINE; TERBINAFINE;

ASPERGILLUS FUMIGATUS; BIOACCUMULATION; BIOSYNTHESIS; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CROSS RESISTANCE; CRYPTOCOCCUS NEOFORMANS; DRUG SENSITIVITY; FEEDBACK SYSTEM; GENE EXPRESSION; HISTOPLASMA CAPSULATUM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOSIS; NONHUMAN; PYRIMIDINE SYNTHESIS; RECURRENT INFECTION; REVIEW; SACCHAROMYCES CEREVISIAE; STANDARDIZATION; THRUSH; TREATMENT FAILURE;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, MICROBIAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 0032319012     PISSN: 09668454     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Becq-Sagué CM, Jarvis WR, the National Nosocomial Infections Surveillance Program. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-90. J Infect Dis 1993; 167: 1247-51.
2. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 18: 1274.
3. Wingard JR, Merz WG, Rinaldi MG. et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-9.
4. Pfaller M. Epidemiology and control of fungal infections. Clin Infect Dis 1994; 19 (Suppl. 1): S8-13.
5. Nguyen MH, Peacock JE, Morris AJ. et al. The changing face of candidemia: emergence of non- Candida albicans species and antifungal drug resistance. Am J Med 1996; 100: 617-23.
6. Odds FC. Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects. Int J Antimicrob Agents 1996; 6: 141-4.
7. Polak A, Hartman PG. Antifungal chemotherapy - are we winning? Prog Drug Res 1991; 37: 181-269.
8. Rex JH, Pfaller MA, Galgiani JN. et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-47.
9. Vanden Bossche H, Warnock DW, Dupont B. et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994; 32 (Suppl. 1): 189-202.
10. Baily GG, Perry FM, Denning DW, Mandai BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994; 8: 787-92.
11. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993; 31: 2933-7.
12. Cameron ML, Schell WA, Bruch S. et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for the human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37: 2449-53.
13. Newman SL, Flanigan TP, Fisher A. et al. Clinically significant mucosal candidiasis resistant to fluconazole in patients with AIDS. Clin Infect Dis 1994; 19: 684-6.
14. Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS. a therapeutic approach. J Infect 1993; 26: 117-25.
15. Ruhnke M, Eigler A, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-8.
16. Garcia-Hermoso D, Dromer F, Improvisi L, Provost F, Dupont B. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob Agents Chemother 1995; 39: 656-60.
17. Maenza JR, Keruly JC, Moore RD. et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219-25.
18. Tumbarello M, Caldarola G, Tacconelli E. et al. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J Antimicrob Chemother 1996; 38: 691-9.
19. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine (ddI) plus saquinavir. N Engl J Med 1996; 334: 1674-5.
20. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993; 17: 1018-21.
21. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tihalli RN, Kaufman CA. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-46.
22. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994; 19: 687-92.
23. Bart-Delabesse E, van Deventer H, Gocsscns W, Poirot JL, Lioret N, van Belkum A, Dromer F. Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit. J Clin Microbiol 1995; 33: 3278-83.
24. Dromer F, Improvisi L, Dupont B, Eliaszewicz M, Pialoux G, Fournier S, Feuillie V. Oral transmission of Candida albicans isolates between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS 1997; 11: 1095-101.
25. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A, Buisson M, Camerlynck PH. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994; 8: 945-50.
26. Dellion S, Improvisi L, Dupont B, Dromer F. Diversity among yeasts isolated from patients with AIDS and oral candidosis, especially regarding fluconazole susceptibility. J Mycol Méd 1995; 5: 98-101.
27. Lischewski A, Ruhnke M, Tennagen I, Shöman G, Morschháuser J, Hacker J. Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance profiles. J Clin Microbiol 1995; 33: 769-71
28. Rex JR, Pfaller MA, Barry AL, Nelson PW, Webb CD for the NIAID Mycoses Study Group and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-5.
29. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1530-3.
30. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kaufman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495-7.
31. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: Current status of the correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489-95.
32. Correa AL, Velez G, Albert M, Luther M, Rinaldi MG, Graybill JR. Comparison of D0870 and fluconazole in the treatment of murine cryptococcal meningitis. J Med Vet Mycol 1995; 33: 367-74.
33. Velez J, Allendoerfer R, Rinaldi MG, Luther M, Graybill JR. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993; 168: 508-10.
34. Armengou A, Porcar C, Mascaro J, Garcia-Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23: 1337-8.
35. Coker RJ, Harris JRW. Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels (Letter). J Infect 1991; 23: 101-3.
36. Currie BP, Ghannoum M, Bessen L, Casadevall A. Decreased fluconazole susceptibility of a relapse Cryptococcus neoformans isolate after fluconazole treatment. Infect Dis Clin Pract 1995; 4: 318-9.
37. Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Tourte-Schaefer C, Skard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis, 1994, 19: 975-6.
38. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993; 37: 1383-6.
39. Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC, Edwards JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 30: 2881-6.
40. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MAE, Haubrich RH, Richie JA, Edwards JE, Ghannoum MA. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322-8.
41. Lamb DC, Corran A, Baldwin BC, Kwon-Chung J, Kelly SL. Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. Febs Lett 1995; 368: 326-30.
42. Joseph-Home T, Hollomon D, Loeffler RST, Kelly SL. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 1995; 39: 1526-9.
43. Currie B, Sanati H, Ibrahim AS, Edwards JE, Casadevall A, Ghannoum MA. Sterol compositions and susceptibilites to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother 1995a; 39 1934-7.
44. Powderly WG, Keath EJ, Sokol-Anderson M, Robinson K, Kitz D, Little JR, Kobayashi G, Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS. Infect Dis Clin Pract 1992; 1: 314-6.
45. 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. Fems Microbiol Lett 1994; 122: 39-42.
46. Rex JH, Cooper CR, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906-9.
47. Wanger A, Mills K, Nelson PW, Rex JH, Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2.
48. Lozano-Chiu M, Ghannoum MA, Belanger P, Rex JH. Effect of media on detection of amphotericin B (AmB)-resistant Cryptococcus neoformans. 97th General Meeting of the American Society for Microbiology 1997 Abstract no. C-251.
49. Block ER, Jennings AE, Bennett JE. 5-fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother 1973; 3: 649-56.
50. Polak A. 5-Fluorocytosine-current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol 1977; 4: 158-67.
51. Whelan WL. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit Rev Microbiol 1987; 15: 45-56.
52. Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994; 2: 393-400.
53. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992; 15: 21-34.
54. Polak A. Mode of action of 5-fluorocytosine and 5-fluorouracil in dematiacious fungi. Sabouraudia 1983; 21: 15-26.
55. Espinel-Ingroff A, Bartlett M, Bowden R. et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptility testing of filamentous fungi. J Clin Microbiol 1997; 35: 139-43.
56. Oakley KL, Morrissey G. Denning DW. Etficacy of SCH 56592 in 2 immunocompromised murine models of invasive aspergillosis. 36th Interscience Conference on Antunicrob Agents Chemother 1996 Abstract no. F-97.
57. Calhoun DL, Washkin H, White MP, Bonner JR, Mulholland JH, Rumans LW, Stevens DA, Galgiani JN. Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis 1991; 13: 47-51.
58. Galgiani JN, Stevens DA, Graybill JR, Dismukes WE, Cloud GA. Ketoconazole therapy of progressive coccidioidomycosis: Comparison of 400- and 800-mg doses and observations at higher doses. Am J Med 1988; 84: 603-10.
59. Huppert M, Pappagianis D, Sun SH, Gleason-Jordan I, Collins MS, Vukovich KR. Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. Antimicrob Agents Chemother 1976; 9: 406-13.
60. Shadomy S, White SC, Yu HP, Dismukes WE. the NIAID Mycoses Study Group. Treatment of systemic mycoses with ketoconazole: In vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis 1985; 152: 1249-56.
61. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, Lee J, Callender D, Rubin M, Pizzo PA. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616-22.
62. Smedema M, Connolly P, Durkin M, Wheat H, Wheat J, Hafner R. Antifungal susceptibility testing on isolates of Histoplasma capsulatum obtained from a clinical trial evaluating fluconazole treatment in patients with AIDS. 96th General Meeting of the American Society for Microbiology 1996 Abstract no. F-65.
63. Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother 1997; 41: 410-4.
64. D'Antonio D, Mazzoni A, Iacone A, Violante B, Capuani MA, Schioppa F, Romano F. Emergence of fluconazole-resistant strains of Blastochizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 1996; 34: 753-5.
65. Kenna S, Bligh HFJ, Kelly SL. Genetic and physiological analysis of azole sensitivity in Saccharomyces cerevisiae. J Med Vet Mycol 1989; 27: 397-406.
66. Watson PF, Rose ME, Kelly SL. Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae. J Med Vet Mycol 1988; 26: 153-62.
67. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-91.
68. Marichal P, Vanden Bossche H. Mechanisms of resistance to azole antifungals. Acta Biochim Pol 1995; 42: 509-16.
69. Vanden Bossche H. Chemotherapy of human fungal infections. In: Lyr H, ed. Modern Selective Fungicides. Properties, Applications, Mechanisms of Action. Jena: Gustav Fisher 1995; 431-84.
70. Kerridge D, Fasoli M, Wayman JF. Drug resistance in Candida albicans and Candida glabrata. Ann NY Acad Sci 1988; 544: 245-59
71. Pfaller MA, Messer SA, Hollis RJ. Strain delineation an antifungal susceptibilities of epidemiologically releated and unrelated isolates of Candida lusitaniae. Diagnostic Microbiology and Infectious Disease 1994; 20: 127-33.
72. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 1996; 348: 1523-24.
73. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, Geller R, Wingard JR Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 44: 196-99.
74. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3§,6α-diol. Biochem Biophys Res Comm 1995; 207: 910-15.
75. Sokol-Anderson ML, Sligh JEJ, Elberg S, Brajtburg J, Kobayashi GS, Medoff G. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 1988; 32: 702-05.
76. Holt RJ, Azmi A. Miconazole-resistant Candida. Lancet 1978; 1: 50-51.
77. Horsburgh CR, Kirkpatrick CH. Long-term therapy of chroninc mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983; 74 (Suppl. 1B): 23-29.
78. Johnson EM, Richardson MD, Warnock DW. In vitro resistance with imidazole antifungals in Candida albicans. J Antimicrob Chemother 1984; 13: 541-58.
79. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhinechalberg J, Pfaller M Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS - documentation by in vitro susceptibility testing and DNA subtype analysis. Clinical Infectious Diseases 1994; 18: 240-42.
80. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86.
81. Hitchcock CA, Barrett BK, Russell NJ. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol 1986, 132: 2421-31.
82. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC-transporter gene. Microbiol 1997; 143: 405-16.
83. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Resistance to fluconazole in Candida albicans from aids patients correlated with reduced intracellular accumulation of drug. FEMS Microbiology Letters 1995; 131: 337-41.
84. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993; 37: 1962-65.
85. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995; 39: 1696-99.
86. Vanden Bossche H, Marichal P, Odds F, Lejeune L, Coene MC. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36: 2602-10.
87. Marichal P, Gorrens J, Coene MC, Le Jeune L, Vanden Bossche H. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 1995; 38: 111-17.
88. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother 1996; 40: 2443-6.
89. Balzi E, Goffeau A. Genetics and biochemistry of yeast multidrug resistance. Biochem Biophys Acta 1994; 1187: 152-62.
90. Miyahara K, Hirata D Miyakawa T. yAP-1- and yAP-2-mediated, heat shock-induced transcriptional activation of the multidrug resistance ABC transporter genes in Saccharomyces cerevisiae. Current Genetics 1996; 29: 103-05.
91. Wemmie JA, Szczypka MS, Thiele DJ, Moye RW. Cadmium tolerance mediated by the yeast AP-1 protein requires the presence of an ATP-binding cassette transporter-encoding gene, YCFI. J Biol Client 1994; 269: 32592-97.
92. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PAJ. Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans 1990; 18: 56-59.
93. Lai MH, Kirsch DR. Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucl Acids Res 1989; 17: 804.
94. Marichal P, Vanden Bossche H, Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997; 41: 2229-37.
95. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, Bennett JE Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition. and antifungal susceptibility. Antimicrob Agents Chemother 1995; 39: 2708-17.
96. Ryder NS Squalene epoxidase as a target of the allylamines. Biochem Soc Trans 1991; 19: 774-77.
97. Landl KM, Klosch B, Turnowsky F. ERG1, encoding squalene epoxidase, is located on the right arm of chromosome VII of Saccharomyces cerevisiae. Yeast 1996; 12(6): 609-13.
98. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-05.
99. Mercer EI. Morpholine antifungals and their mode of action. Biochem Soc Trans 1991; 19: 788-93.
100. Mariceau C, Guyonnet D, Karst F. Construction and growth properties of a yeast strain defective in sterol 14-reductase. Current Genet 1992; 22: 267-72.
101. Lorenz T, Parks LW Cloning, sequencing, and disruption of the gene encoding sterol C-14 reductase in Saccharomyces cerevisiae. DNA and Cell Biol 1992; 11: 685-92.
102. Lees ND., Skaggs B, Kirsch DR, Bard M. Cloning of the late genes in ergosterol biosynthetic pathway of Saccharomyces cerevisiae - a review. Lipids 1995; 30: 221-26.
103. Lai MH, Bard M, Pierson CA, Alexander JF, Goebl M, Carter GT, Kirsch DR. The identification of a gene family in the Saccharomyces cerevisiae ergosterol biosynthesis pathway. Gene 1994; 140: 41-9.
104. th Interscience Conference on Antimicrobial Agents Chemotherapy 1996, Abstract No F-27.
105. th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996, Abstract No. F-46.
106. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol 1994; 48: 471-97.
107. Mazur P, Monn N, Baginsky W, el-Sherbeini SM, Clemas JA, Nielsen JB, Foor F. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 1995; 15: 5671-81.
108. Douglas CM, Marrinan JA, Li W, Kurtz MB. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. Bacteriol 1994; 176: 5686-96.
109. Kurtz MB, Abruzzo G, Bartizal K, Marrinan JA, Li W, Milligan J, Nollstadt K, Douglas CM. Characterization of echinocandin-resistant mutants of Candida albicans - genetic, biochemical, and virulence studies. Infect Immun 1996; 64: 3244-51.